- Previous Close
46.34 - Open
49.15 - Bid 58.76 x 700
- Ask 59.72 x 300
- Day's Range
45.35 - 61.55 - 52 Week Range
20.88 - 61.55 - Volume
2,487,046 - Avg. Volume
245,234 - Market Cap (intraday)
430.67M - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
29.05 - EPS (TTM)
2.04 - Earnings Date Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
40.00
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
www.semlerscientific.comRecent News: SMLR
View MorePerformance Overview: SMLR
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SMLR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SMLR
View MoreValuation Measures
Market Cap
430.67M
Enterprise Value
418.09M
Trailing P/E
29.05
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.81
Price/Book (mrq)
5.05
Enterprise Value/Revenue
7.09
Enterprise Value/EBITDA
20.21
Financial Highlights
Profitability and Income Statement
Profit Margin
27.00%
Return on Assets (ttm)
14.60%
Return on Equity (ttm)
20.39%
Revenue (ttm)
58.94M
Net Income Avi to Common (ttm)
15.91M
Diluted EPS (ttm)
2.04
Balance Sheet and Cash Flow
Total Cash (mrq)
12.67M
Total Debt/Equity (mrq)
0.11%
Levered Free Cash Flow (ttm)
-56.74M